Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Exscientia Ltd.. (3/4/21). "Press Release: Exscientia Completes $100 Million Series C Financing Round with BlackRock Funds".

Organisations Organisation Exscientia Ltd. (ex scientia)
  Group Exscientia (Group)
  Organisation 2 BlackRock (Group)
Products Product AI-based drug discovery
  Product 2 private equity
Index terms Index term Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors
  Index term 2 Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock
Persons Person Abecassis, William (BlackRock 202103 Head of Innovation Capital)
  Person 2 Hopkins, Andrew (Ex Scientia 201604 CEO)
     


Proceeds to further accelerate AI drug discovery platform and pipeline


Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding.

This new capital will be used to support Exscientia’s platform development towards autonomous drug design. In addition, the company will extend its proprietary pipeline into clinical trials and expand existing capabilities in biological analytics that support target selection and portfolio development.

With the company’s end-to-end AI-first drug discovery platform, CentaurAI™, Exscientia has been able to generate novel drugs and overcome conventional drug discovery limitations several years faster than industry benchmarks. Exscientia has demonstrated the platform’s capabilities by creating the first fully AI-designed drug to enter clinical trials and advancing multiple drug candidates into preclinical testing. In addition to its growing proprietary pipeline, the company has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer and Dainippon Sumitomo as well as several biotech companies.

“Exscientia is breaking ground in small molecule drug design, with a platform that radically improves drug discovery” says William Abecassis, Head of BlackRock’s Innovation Capital who will join Exscientia’s Board of Directors as an observer. “We are thrilled to be investing in this world-class team, who are already delivering results with AI-designed drugs now entering clinical trials."

Andrew Hopkins, CEO of Exscientia added, “We are delighted that BlackRock shares our vision for revolutionising how drugs are discovered. It is also recognition of the ingenuity and hard work of our employees to turn the promise of AI into reality today, where we are bringing the world’s first AI designed drugs into the clinic. BlackRock’s investment is an important step in our vision that all drugs will be designed by AI. I believe that our company’s reimagined approach to drug discovery will become the new de facto standard”

Exscientia has doubled in size over the past year and expects to double again in 2021, including a recent US expansion into Miami and Boston. The company employs over 100 people from over 20 different nations, with equal balance of technologists and drug discovery scientists, of which 60% are PhDs. Exscientia is named the fastest growing private biotech or pharmaceutical company in the UK in the 2021 Alantra Pharma Fast 50 as well as one of the fastest growing healthcare companies in the Financial Times FT1000.


ENDS


About Exscientia

Exscientia is an Artificial Intelligence (AI)-driven pharmatech committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform the how drugs are created.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI


PR Contacts:

Edelman Public Relations:
Stephanie Crisp
P: +44 (0)75 8300 3417
stephanie.crisp@edelman.com

For Exscientia
Mark Swindells, Chief Commercial Officer
contact@exscientia.ai

   
Record changed: 2021-04-21

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Exscientia (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top